Cytochroma

Cytochroma is a clinical-stage specialty pharmaceutical company that designs, develops, and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The company has an advanced portfolio of novel therapies aimed at safely and effectively treating patients with vitamin D insufficiency and SHPT associated with stage 3, 4, or 5 CKD. Additionally, Cytochroma is developing new therapies for elevated phosphate levels (hyperphosphatemia) to improve SHPT control in CKD patients.